REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/02/2025
Back to search
Official data from USPTO
PHARNEXT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
PHARNEXT
ST13
US500000088424864Class
5, 35, 41, 42, 44
Filing
88424864
Registration
6066907
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
06/03/2025
Classification
Registered
Trademark type
Word
Nice classes
5, 35, 41, 42, 44
Filing date
05/10/2019
Registration date
06/02/2020
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/02/2020
Last transaction
06/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
99
Owner location
ISSY-LES-MOULINEAUX, FR
Examiner
REED, MAUREEN
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
PHARNEXT
Representatives
Carlynn Ferguson Davis IPHORGAN LTD.
Technical classification
Nice Classes
Class 5Class 35Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicinemedicines for the treatment of neurologicalneurodegenerativeneuromuscular and neuropathic diseasestraumatic neuropathies and demyelinating neuropathiesautoimmune diseasescancerscardiovascular diseasesmetabolic syndromes; pharmaceutical products for human use for the treatment of neurologicalneurodegenerativeneuromuscular and neuropathic diseasestraumatic neuropathies and demyelinating neuropathiesautoimmune diseasescancerscardiovascular diseasesmetabolic syndromes; pharmaceutical preparations for human or veterinary use for the treatment of neurologicalneurodegenerativeneuromuscular and neuropathic diseasestraumatic neuropathies and demyelinating neuropathiesautoimmune diseasescancerscardiovascular diseasesmetabolic syndromes; biological preparations for medical purposes for the treatment of neurologicalneurodegenerativeneuromuscular and neuropathic diseasestraumatic neuropathies and demyelinating neuropathiesautoimmune diseasescancerscardiovascular diseasesmetabolic syndromes; diagnostic preparations for medical diagnosis purposes; chemical preparations for medical purposesfor the treatment of neurologicalneurodegenerativeneuromuscular and neuropathic diseasestraumatic neuropathies and demyelinating neuropathiesautoimmune diseasescancerscardiovascular diseasesmetabolic syndromes; food supplements and nutritional supplements for medical purposes; dietetic foods and beverages adapted for medical and pharmaceutical purposes; homeopathic and phyto-therapeutic supplements; disinfectants for hygiene purposes for medicine; bath preparations for medical purposes; dietetic beverages adapted for medical purposes; chemical reagents for medical usebiomarkers; products for personal hygiene for medical purposesmedical soaps; plasters and gauze for dressings for medical purposes; medical dressingsexcept instruments
Class 35
Creationcompilation and management of databases and central data files in the field of pharmaceutical research and developmentmedicinegenetics and clinical trials; compilation of statistics in the field of health and medicine; collection and systematization of data in a central file in the field of pharmaceutical research and developmenthealth and medicine; public relations in the field of health and medicine
Class 41
training services in the fields of healthpharmaceutical and medical researchpharmaceutical and medical development; publication of books and texts other than publicity texts in the pharmaceuticalmedical and health fields; educational servicesarranging and conducting educational colloquiumsconferencescongressesseminars in the fields of pharmaceuticalsmedical and health; teaching in the pharmaceuticalmedical and health fields
Class 42
pharmaceutical products development; pharmaceutical research and development; conducting tests on pharmaceutical products; conducting clinical trials for pharmaceutical products for others; scientific research in the field of medicine; bioinformaticschemical and biological analysis; scientific research in chemistrycosmetologybiologybacteriologynutritionbiotechnology; biological research and bioinformatics services in the field of chemicalbiological and pharmaceutical products; software development and design in the field of pharmaceutical researchhealth and medicine; provision of scientific information relating to pharmaceutical products and medical and scientific research in the field of pharmaceuticals products and clinical trials; scientific research on chemical reagents for medical usebiomarkers; pharmaceutical research services
Class 44
medical services; pharmaceutical advice services; pharmacy consultation; medical advisory and information services relating to pharmaceutical products; medical information services; provision of medical information; providing health information services on the treatment of diseases through an awareness program
Publications
History of USPTO decisions and trademark events.
25 publications found
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
06/23/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
01/12/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
06/02/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/17/2020
PUBO
PUBLISHED FOR OPPOSITION
03/17/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/26/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/12/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
02/12/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/12/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
02/12/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/12/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/04/2020
ALIE
ASSIGNED TO LIE
02/03/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/29/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/01/2019
GNRT
NON-FINAL ACTION E-MAILED
08/01/2019
CNRT
NON-FINAL ACTION WRITTEN
08/01/2019
DOCK
ASSIGNED TO EXAMINER
07/25/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/25/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
05/25/2019
ALIE
ASSIGNED TO LIE
05/22/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
05/15/2019
NWAP
NEW APPLICATION ENTERED
05/14/2019
Continuous trademark protection
Get notified about every new filing that threatens PHARNEXT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.